[
    "disease or condition); and/or c) relieving the disease, that is, causing the regression of clinical symptoms (e.g., ameliorating the disease state, providing partial or total remission of the disease or condition, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival. </p>[0046] \u201cPrevention\u201d or\u201cpreventing\u201d means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop. Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition. </p>[0047] \u201cSubject\u201d refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation or experiment. The methods described herein may be useful in human therapy and/or veterinary applications. In some embodiments, the subject is a mammal. In one embodiment, the subject is a human. </p>[0048] The term\u201ctherapeutically effective amount\u201d or\u201ceffective amount\u201d of a compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof means an amount sufficient to effect treatment when administered to a subject, to provide a therapeutic benefit such as amelioration of symptoms or slowing of disease progression. For example, a therapeutically effective amount may be an amount sufficient to decrease a symptom of a disease or condition responsive to inhibition of IDO1 activity. The therapeutically effective amount may vary depending on the subject, and disease or condition being treated, the weight and age of the subject, the severity of </p>13 </p>604642.1 \n\n Attorney Docket No.: 1115.PF the disease or condition, and the manner of administering, which can readily be determined by one or ordinary skill in the art. </p>[0049] The term\u201cinhibition\u201d indicates a decrease in the baseline activity of a biological activity or process.\u201cInhibition of activity of IDO1\u201d or variants thereof refers to a decrease in activity in IDO1 as a direct or indirect response to the presence of a compound of the present application relative to the activity IDO1in the absence of the compound of the present application.\u201cInhibition of IDO1\u201d refers to a decrease in IDO1 activity as a direct or indirect response to the presence of a compound described herein relative to the activity of IDO1 in the absence of the compound described herein. In some embodiments, the inhibition of IDO1 activity may be compared in the same subject prior to treatment, or other subjects not receiving the treatment. </p> Compounds </p>[0050] Provided herein are compounds that function as inhibitors of IDO1. In one aspect, provided is a compound having structure of Formula I: </p><img id=\"imgf000016_0001\" path=\"imgf000016_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/362182013/WO/20161124/A1/002016/18/69/67/imgf000016_0001.tif\"/>\n wherein </p> R<sup>1</sup> is mono or bicyclic aryl or heteroaryl, wherein each mono or bicyclic aryl or heteroaryl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> haloalkoxy, C<sub>1</sub>-<sub>6</sub> alkoxy, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, and C<sub>3-6</sub> cycloalkyl, wherein two of the optional substituents can join to form an additional partially saturated heterocyclic ring; and </p> wherein each C<sub>1</sub>-<sub>6</sub> alkoxy, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, and C<sub>3-6</sub> cycloalkyl is optionally substituted with one, two, or three substituents independently selected from hydroxyl, halo, -CN, - N(R<sup>20</sup>)(R<sup>22</sup>) and C<sub>3-6</sub> cycloalkyl; 14 </p>604642.1 \n\n Attorney Docket No.: 1115.PF X is N or CR<sup>2c</sup>; </p> R<sup>2a</sup>, R<sup>2b</sup>, and R<sup>2c</sup> are independently hydrogen, ",
    "lly in an individual. \u201cEx vivo\u201d means outside of a living individual. Examples of ex vivo cell populations include in vitro cell cultures and biological samples including fluid or tissue samples obtained from individuals. Such samples may be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. Exemplary tissue samples include tumors and biopsies thereof. In this context, the invention may be used for a variety of purposes, including therapeutic and experimental purposes. For example, the invention may be used ex vivo to determine the optimal schedule and/or dosing of administration of an IDO1 inhibitor for a given indication, cell type, individual, and other parameters. Information gleaned from such use may be used for experimental purposes or in the clinic to set protocols for in vivo treatment. Other ex vivo uses for which the invention may be suited are described below or will become apparent to those skilled in the art. The selected compounds may be further </p>characterized to examine the safety or tolerance dosage in human or non-human subjects. Such properties may be examined using commonly known methods to those skilled in the art. [0102] In some embodiments, the compounds described herein may be used to treat subjects who have or are suspected of having disease states, disorders, and conditions (also collectively referred to as\u201cindications\u201d) responsive or believed to be responsive to the inhibition of IDO1 activity. In some embodiments, the compounds described herein may be used to inhibit the activity of an IDO1 polypeptide. In some embodiments, the compounds described herein may be used to inhibit excessive or destructive immune reactions or growth or a proliferation of a cell, such as a cancer cell, or inhibit immunosuppression. [0103] Example indications suitable for treatment with compounds described here include, without limitation cancer, viral infection such as HIV infection, HBV infection, HCV infection, other infections (e.g., skin infections, GI infection, urinary </p> 54 </p>604642.1 \n\n Attorney Docket No.: 1115.PF tract infections, genito-urinary infections, and systemic infections), depression, neurodegenerative disorders such as Alzheimer's disease and Huntington's disease, trauma, age-related cataracts, organ transplantation (e.g., organ transplant rejection), and autoimmune diseases. [0104] Examples of autoimmune diseases include, but are not limited to, asthma, collagen diseases such as rheumatoid arthritis, systemic lupus erythematosus. Sharp's syndrome, CREST syndrome (calcinosis, Raynaud's syndrome, esophageal dysmotility, sclerodactyly, telangiectasia), dermatomyositis, vasculitis (Morbus Wegener's) and Sj\u00f6gren's syndrome, renal diseases such as Goodpasture's syndrome, rapidly- progressing glomerulonephritis and membrano-proliferative glomerulonephritis type II, endocrine diseases such as type-I diabetes, autoimmune polyendocrinopathy-ca",
    "adder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck </p> 55 </p>604642.1 \n\n Attorney Docket No.: 1115.PF cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors (e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, or soft tissue sarcoma. In some embodiments, the solid tumor is from non-small cell lung cancer, small-cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, or breast cancer.. [0107] In some embodiments, the disease is an autoimmune disease. In particular embodiments, the autoimmune disease is systemic lupus erythematosus (SLE), myestenia gravis, rheumatoid arthritis (RA), acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis (MS), psoriasis, Sjoegren\u2019s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, or chronic obstructive pulmonary disease (COPD). In other embodiments, the disease is inflammation. In yet other embodiments, the disease is excessive or destructive immune reactions, such as asthma, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease (COPD), and lupus. [0108] Provided is a method for treating a subject, who has or is suspected of having a disease or condition responsive or believed to be responsive to the inhibition of IDO1 activity by administering to the subject the compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof. Provided is also a method of inhibiting kinase activity of a IDO1 polypeptide by contacting the polypeptide with the compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof. Provided is also a method of inhibiting a growth or a proliferation of cancer cells of hematopoietic origin comprising contacting the cancer cells with an effective amount of a compound described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof. [0109] In one embodiment, the compounds of the present application may be used in combination with one or more additional therapeutic agent that are being used and/or developed to treat cancers or inflammatory disorders. The one or more additional therapeutic agent may be a chemotherapeutic agent, an immunotherapeutic agent, a radiotherapeutic agent, an anti-neoplastic agent, an anti-cancer agent, an anti- proliferation agent, an anti-fibrotic agent, an anti-angiogenic agent, a therapeutic antibody, or any combination thereof. 56 </p>604642.1 \n\n Attorney Docket No.: 1115.PF [0110] The one or more additional therapeutic agent may be an inhibitor to PI3K such as PI3K\u03b3, PI3K\u03b2, PI3K\u03b4, and/or PI3K\u03b1, Janus kinase (JAK) such as JAK1, JAK2 and/or JAK3 , spleen tyrosine kinase (SYK), Bruton\u2019s tyrosine kinase (BTK), bromodomain containing protein inhibitor (",
    "nant human interleukin-2 (Shenzhen Neptunus) and celmoleukin; (26) Nucleoprotein inhibitors (HBV core or capsid protein inhibitors) selected from the group consisting of NVR-1221, NVR-3778, BAY 41-4109, morphothiadine mesilate and DVR-23; (27) Stimulators of retinoic acid-inducible gene 1 selected from the group consisting of SB-9200, SB-40, SB-44, ORI-7246, ORI-9350, ORI-7537, ORI-9020, ORI- 9198 and ORI-7170; (28) Stimulators of NOD2 selected from the group consisting of SB-9200; (29) Recombinant thymosin alpha-1 selected from the group consisting of NL-004 and PEGylated thymosin alpha 1; (30) Hepatitis B virus replication inhibitors selected from the group consisting of isothiafludine, IQP-HBV, RM-5038 and Xingantie; (31) PI3K inhibitors selected from the group consisting of idelalisib, AZD-8186, buparlisib, CLR-457, pictilisib, neratinib, rigosertib, rigosertib sodium, EN-3342, TGR-1202, alpelisib, duvelisib, UCB-5857, taselisib, XL-765, gedatolisib, VS- 5584, copanlisib, CAI orotate, perifosine, RG-7666, GSK-2636771, DS-7423, panulisib, GSK-2269557, GSK-2126458, CUDC-907, PQR-309, INCB-040093, pilaralisib, BAY-1082439, puquitinib mesylate, SAR-245409, AMG-319, RP- 6530, ZSTK-474, MLN-1117, SF-1126, RV-1729, sonolisib, LY-3023414, SAR- 260301 and CLR-1401; (32) cccDNA inhibitors selected from the group consisting of BSBI-25; 74 </p>604642.1 \n\n Attorney Docket No.: 1115.PF (33) PD-L1 inhibitors selected from the group consisting of MEDI-0680, RG-7446, durvalumab, KY-1003, KD-033, MSB-0010718C, TSR-042, ALN-PDL, STI- A1014 and BMS-936559; (34) PD-1 inhibitors selected from the group consisting of nivolumab, </p> pembrolizumab, pidilizumab, BGB-108 and mDX-400; (35) BTK inhibitors selected from the group consisting of ACP-196, dasatinib, </p> ibrutinib, PRN-1008, SNS-062, ONO-4059, BGB-3111, MSC-2364447, X-022, spebrutinib, TP-4207, HM-71224, KBP-7536 and AC-0025; (36) Other drugs for treating HBV selected from the group consisting of gentiopicrin (gentiopicroside), nitazoxanide, birinapant, NOV-205 (Molixan; BAM-205), Oligotide, Mivotilate, Feron, levamisole, Ka Shu Ning, Alloferon, WS-007, Y- 101 (Ti Fen Tai), rSIFN-co, PEG-IIFNm, KW-3, BP-Inter-014, oleanolic acid, HepB-nRNA, cTP-5 (rTP-5), HSK-II-2, HEISCO-106-1, HEISCO-106, </p> Hepbarna, IBPB-006IA, Hepuyinfen, DasKloster 0014-01, Jiangantai </p> (Ganxikang), picroside, GA5 NM-HBV, DasKloster-0039, hepulantai, IMB- 2613, TCM-800B, reduced glutathione and ZH-2N; and (37) The compounds disclosed in US20100143301 (Gilead Sciences), </p> US20110098248 (Gilead Sciences), US20090047249 (Gilead Sciences), US8722054 (Gilead Sciences), US20140045849 (Janssen), US20140073642 (Janssen), WO2014/056953 (Janssen), WO2014/076221 (Janssen), </p> WO2014/128189 (Janssen), US20140350031 (Janssen), WO2014/023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array </p> Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx",
    "tin, derivatives of quercetin, S-1360, AR- 177, L-870812, and L-870810, raltegravir, BMS-538158, GSK364735C, BMS-707035, MK- 2048, BA 011, elvitegravir, dolutegravir and GSK-744; (5) HIV non-catalytic site, or allosteric, integrase inhibitors (NCINI) including, but not limited to, BI-224436, CX0516, CX05045, CX14442, compounds disclosed in WO 2009/062285 (Boehringer Ingelheim), WO 2010/130034 (Boehringer Ingelheim), WO 2013/159064 (Gilead Sciences), WO 2012/145728 (Gilead Sciences), WO 2012/003497 (Gilead Sciences), WO 2012/003498 (Gilead Sciences) each of which is incorporated by references in its entirety herein; (6) gp41 inhibitors selected from the group consisting of enfuvirtide, sifuvirtide, albuvirtide, FB006M, and TRI-1144; (7) the CXCR4 inhibitor AMD-070; (8) the entry inhibitor SP01A; (9) the gpl20 inhibitor BMS-488043; 86 </p>604642.1 \n\n Attorney Docket No.: 1115.PF (10) the G6PD and NADH-oxidase inhibitor immunitin; (11) CCR5 inhibitors selected from the group consisting of aplaviroc, vicriviroc, maraviroc, cenicriviroc, PRO-140, INCB15050, PF-232798 (Pfizer), and CCR5mAb004; (12) CD4 attachment inhibitors selected from the group consisting of ibalizumab (TMB-355) and BMS-068 (BMS-663068); (13) pharmacokinetic enhancers selected from the group consisting of cobicistat and SPI-452; and (14) other drugs for treating HIV selected from the group consisting of BAS-100, SPI- 452, REP 9, SP-01A, TNX-355, DES6, ODN-93, ODN-112, VGV-1, PA-457 (bevirimat), HRG214, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO-025, BAY 50-4798, MDX010 (ipilimumab), PBS 119, ALG 889, and PA- 1050040 (PA-040), and combinations thereof . [0165] In certain embodiments, the additional therapeutic agent is a Toll-like receptor 8 modulator selected from the group consisting of motolimod, resiquimod, 3M- 051, 3M-052, MCT-465, IMO-4200, VTX-763, VTX-1463 and those disclosed in US20140045849 (Janssen), US20140073642 (Janssen), WO2014/056953 (Janssen), WO2014/076221 (Janssen), WO2014/128189 (Janssen), US20140350031 (Janssen), WO2014/023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma), </p> US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (VentirxPharma), US20140275167 (Novira therapeutics), </p>US20130251673 (Novira therapeutics). [0166] In certain embodiments, a compound disclosed herein, or a </p>pharmaceutically acceptable salt thereof, is combined with one, two, three, four or more additional therapeutic agents. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with two additional therapeutic agents. In other embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with three additional therapeutic agents. In further embodiments, a compound disclosed herein, or a pharmaceut",
    "-2-((l-(oxetan-3- yl)pyrrolidin-3-yl)amino)-iH-imidazo[4,5-Z&gt;]pyridine-7-carboximidamide </p><img id=\"imgf000443_0001\" path=\"imgf000443_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/362181085/WO/20161124/A1/002016/18/69/67/imgf000443_0001.tif\"/></p>[01003] Example 508 was made analogously to Example 229 using 3-(2-chloro-l-((2- (trimethylsilyl)ethoxy)methyl)-lH-imidazo[4,5-b]pyridin-7-yl)-4-(3-chloro-4- fluorophenyl)-l,2,4-oxadiazol-5(4H)-one and (i?)-l-(oxetan-3-yl)pyrrolidin-3-amine in place of 3-(2-chloro-4,5-difluoro-l-((2-(trimethylsilyl)ethoxy)methyl)-lH- benzo[d]imidazol-7-yl)-4-(3-chloro-4-fluorophenyl)-l,2,4-oxadiazol-5(4H)-one and 3- aminopropanamide hydrochloride, respectively. The TFA salt of (i?)-N-(3-chloro-4- fluorophenyl)-N'-hydroxy-2-((l-(oxetan-3-yl)pyrrolidin-3-yl)amino)-7H-imidazo[4,5- Z&gt;]pyridine-7-carboximidamide was isolated as an off-white solid. C2<sub>0</sub>H21CIFN7O2. 446.4/448.2 (M+l). \u00be NMR (400 MHz, DMSO-d6) \u03b4 11.30 (br. s, 1H), 8.93 (s, 1H), 7.99 (d, J = 6.1 Hz, 1H), 7.09 (t, J = 9.0 Hz, 1H), 7.03 - 6.92 (m, 2H), 6.58 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 4.78 (t, J = 7.4 Hz, 2H), 4.69 - 4.55 (m, 3H), 4.47 (m, 1H), 3.8 - 3.3 (m, 5H), 2.09 (d, J = 11.6 Hz, 1H).<sup>19</sup>F NMR (376 MHz, DMSO-d6) \u03b4 -74.6, -126.7. </p>Biological Examples </p> [01004] Activity testing was conducted in the Examples below using methods described herein and those well known in the art. </p>Example 509. Cell-based (HeLa) Assay for Measurement of IDOl Inhibition </p> [01005] To measure IDOl inhibition in tissue culture, HeLa cells were treated with a test compound in the presence of IFNy, which induces IDOl expression. Following incubation, cell supematants were assayed for kynurenine levels, an indicator of IDOl activity. </p>[01006] HI -HeLa cells (ATCC #CRL-1958) were seeded in 384-well plates (Greiner #82051-282) at a volume of 50 ulVwell in DMEM (Corning #15-018-CM) supplemented \n\n with 10% FBS (Corning #35-011-CV) and 1% P/S/G (Corning #30-009-CL) at a density of 1,250 cells/well and incubated overnight at 37\u00b0C, 5% CO<sub>2</sub>/100% humidity. The following day, the test compounds were added in DMSO (0.5% final) at various concentrations, and IDOl was inducibly expressed by the addition of 50 uL/well of 50ng/mL of INFy (Peprotech #300-02) in cell plating media. As a positive control, 50 uL of the cell plating media without IFNy was added to several wells. Following a 48 hour incubation, the plates were spun down at 1,200 RPM for 5 min at 10 \u00b0C. 65 \u03bc\u03af\u039b \u03b2\u0399\u0399 of the supernatant was then transferred to new 384-well plates (Thermo #262160) that contained 10 uL/well of 30% TCA (Sigma #T0699), and the plates were sealed and incubated at 60\u00b0C for 30 min. The plates were then centrifuged for 15 min at 2,000 RPM at 10 \u00b0C. 40 \u03bc\u03af\u039b \u03b2\u0399\u0399 of the supernatant was transferred to new 384-well plates (Thermo #262160) and was reacted with 40 \u03bc\u0395\u039b \u03b2\u0399\u0399 of 2% (w/v) p-dimethlyaminobenzaldehyde (Sigma #156417) in glacial acetic acid (Sigma #A6283). The reaction was incubated at room temperature for 10 min and absorbance at 480 nm was read using a PerkinElmer Envision plate reader. </p>[01007] Data in Table 1 were normalized based on positive (- IFNy) and negative (+ IFNy) controls and EC50 values were calculated from the fit of the dose-response curves to a four-parameter equation. All EC50 values represent geometric mean values of a minimum of four determinations. These assays generally produced results within 2-fold of the reported mean. </p>Table 1 </p><img id=\"imgf000444_0001\" path=\"imgf000444_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/362181787/WO/20161124/A1/002016/18/69/67/imgf000444_0001.tif\"/>\n Example No. Name ECso (nM)</p>N-(3-chloro-4-fluorophenyl)-N'-hydroxy-7-</p>7 (trifluoromethyl)-lH-benzimidazole-4- 926 carboximidamide </p> N-(3-chloro-4-fluorophenyl)-N'-hydroxy-3H-</p>8 1792 benzimidazole-4-carboximidamide </p> N-(3-chloro-4-fluorophenyl)-6-fluoro-N'-</p>9 hydroxy-7-methyl-3H-benzimidazole-4- 634 carboximidamide </p> N-(3-chloro-4-fluorophenyl)-6,7-difluoro-N'-</p>10 438 hydroxy-3H-benzimidazole-4-carboximidamide </p> 6-chloro-N-(3-chloro-4-fluorophenyl)-N'-</p>11 7604 hydroxy-3H-benzimidazole-4-carboximidamide </p> 7-bromo-N-(3-chloro-4-fluorophenyl)-N'-</p>12 660 hydroxy-3H-benzimidazole-4-carboximidamide </p> 2-amino-N-(3-chloro-4-fluorophenyl)-6,7-</p>13 difluoro-N'-hydroxy-3H-benzimidazole-4- 2739 carboximidamide </p> 2-amino-N-(3-bromo-4-fluorophenyl)-6,7-</p>14 difluoro-N'-hydroxy-3H-benzimidazole-4- 494 carboximidamide </p> 2-amino-N-(3-bromophenyl)-6,7-difluoro-N'-</p>15 570 hydroxy-3H-benzimidazole-4-carboximidamide </p> 2-amino-N-(3-chlorophenyl)-6,7-difluoro-N'-</p>16 607 hydroxy-3H-benzimidazole-4-carboximidamide </p> 2-amino-6, 7 -difluoro-N- [4-fluoro-3 -</p>17 (trifluoromethyl)phenyl]-N'-hydroxy-3H- 1092 b"
]